Indication
Hyperlipidemia
39 clinical trials
39 products
1 drug
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3403 in Healthy Volunteers and Subjects With Elevated LDL-CStatus: Not yet recruiting, Estimated PCD: 2025-02-18
Product
SGB-3403Clinical trial
A Parallel, Open-Label, Single-Dose Administration, Phase 1 Clinical Study to Assess the Safety and Pharmacokinetics of AD-104-A in Healthy Adult Volunteers and Patients With Renal ImpairmentStatus: Recruiting, Estimated PCD: 2024-05-01
Product
AD-104-AClinical trial
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With ObesityStatus: Recruiting, Estimated PCD: 2024-07-27
Product
SHR-1918Clinical trial
An Efficacy, Safety Study to Evaluate Multiple Subcutaneous SHR-1918 in Combination With Lipid-Lowering Drugs for the Stable Treatment of Hyperlipidemic Patients With Poor Lipid Control-A Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical StudyStatus: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab. 10/20 mg(Single-layer Tablet) Compared to Ezerosu Tab. 10/20 mg(Double-layer Tablet) in Healthy Adult VolunteersStatus: Completed, Estimated PCD: 2022-03-07
Product
EzerosuProduct
GLY-LOWClinical trial
A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in the Stable Treatment of Patients With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia .Status: Completed, Estimated PCD: 2023-05-23
Product
SHR-1209Clinical trial
A Randomized, Open-label, Multiple-dose, 6-sequence, 3-treatment, 3-period, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2022-10-17
Product
inclisiranClinical trial
A Placebo-controlled, Participant, Investigator and Sponsor Blinded, Randomized Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Inclisiran Treatment Given as Single Subcutaneous Injection in Chinese Participants With Elevated Low-density Lipoprotein Cholesterol (LDL-C) Despite Treatment With LDL-C Lowering Therapies (ORION-14)Status: Completed, Estimated PCD: 2021-10-18
Clinical trial
LAPLACE TIMI 57 - A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With HMG-CoA Reductase Inhibitors in Hypercholesterolemic SubjectsStatus: Completed, Estimated PCD: 2012-04-05
Product
PlaceboProduct
InclisiranClinical trial
A Randomized, Double-blind, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Hypertension and DyslipidemiaStatus: Not yet recruiting, Estimated PCD: 2024-03-01
Product
DWC202206Clinical trial
A Randomised, Double-blind, Placebo Controlled, First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN360 in Subjects With Elevated Lipoprotein(a)Status: Completed, Estimated PCD: 2023-08-23
Clinical trial
The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia - A PhaseⅠb/Ⅱ Randomized, Double-Blind, Placebo-Controlled Clinical StudyStatus: Completed, Estimated PCD: 2020-12-22
Clinical trial
A Non-interventional, Multi Center, Prospective Observational Study to Evaluate the Effect of Improving Systolic Blood Pressure and Low-density Lipoprotein Cholesterol Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab. in Patients With Essential Hypertension and Dyslipidemia.Status: Recruiting, Estimated PCD: 2024-04-01
Product
DWC202207Product
RosuvastatinProduct
EvolocumabProduct
SLN360Product
BR1018-1Product
BR1018-2Clinical trial
A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed DyslipidemiaStatus: Completed, Estimated PCD: 2013-11-12
Product
SimvastatinProduct
EzetimibeClinical trial
A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or LessStatus: Completed, Estimated PCD: 2013-10-10
Product
AtorvastatinProduct
Bempedoic AcidProduct
Bempedoic Acid + EzetimibeClinical trial
A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) During PregnancyStatus: Recruiting, Estimated PCD: 2032-05-01
Product
VupanorsenClinical trial
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF-07285557) in Statin-Treated Participants With DyslipidemiaStatus: Completed, Estimated PCD: 2021-09-29
Clinical trial
A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or LessStatus: Completed, Estimated PCD: 2012-03-02
Clinical trial
Phase 1, Open-label, Single-dose Study of Evolocumab (AMG 145) Administered Subcutaneously to Subjects With Normal Renal Function or Severe Renal Impairment or End Stage Renal Disease Receiving HemodialysisStatus: Completed, Estimated PCD: 2014-12-19
Clinical trial
A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase InhibitorStatus: Completed, Estimated PCD: 2012-05-08
Product
SLx-4090Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Different Doses of SLx-4090 in Combination With a Statin vs. Statin Mono-therapy in Patients With HyperlipidemiaStatus: Completed, Estimated PCD: 2009-09-01
Product
StatinClinical trial
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Compare The Efficacy And Safety Of High-Medium Molecular Weight Beta-Glucan As Add-On To Statin Therapy In Subjects With Hyperlipidemia.Status: Completed, Estimated PCD: 2021-08-31
Product
CP105FClinical trial
Effect of Nigella Sativa on Blood Lipids as an add-on Therapy in Atorvastatin Treated Hyperlipidaemic Patients. A Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-08-31
Product
Nigella SativaClinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Kinetic Effects in Healthy Volunteers With Normal or Mildly Elevated TriglyceridesStatus: Recruiting, Estimated PCD: 2024-06-29
Product
JS401Clinical trial
Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 StudyStatus: Completed, Estimated PCD: 2023-01-28
Clinical trial
Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCIStatus: Recruiting, Estimated PCD: 2024-12-31
Product
LDL reduction therapyClinical trial
Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant PatientsStatus: Recruiting, Estimated PCD: 2024-06-30
Product
PitavastatinProduct
PCSK9 inhibitorClinical trial
Compassionate Use of Metreleptin in Previously-Treated Patients With Partial LipodystrophyStatus: Active (not recruiting), Estimated PCD: 2025-07-31
Product
MetreleptinClinical trial
Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized LipodystrophyStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Development of Low GI Composite Flour and Its Efficacy in Improving the Glycemic Profile in Type 2 Diabetes Patients _ A Randomized Clinical Trial.Status: Completed, Estimated PCD: 2021-12-05
Product
Low GI Composite FlourClinical trial
Lipid Management in Renal Transplant Recipients: A Pilot Study Evaluating the Use of PCSK-9 Inhibitor, Evolocumab.Status: Recruiting, Estimated PCD: 2024-03-01
Product
StatinsClinical trial
PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter StudyStatus: Recruiting, Estimated PCD: 2026-01-30
Product
PCSK 9 InhibitorClinical trial
The Efficacy of Xian-Hua-Cha for Improving Hyperlipidemia Among Obese Population: a Crossover TrialStatus: Recruiting, Estimated PCD: 2024-05-19
Product
Xian-Hua-ChaProduct
PolicosanolClinical trial
Renal Hemodynamic Effects of the HMG-CoA Reductase Inhibitors in Normal Volunteers and in Patients With Chronic Renal FailureStatus: , Estimated PCD: 2007-01-01
Clinical trial
The Role of Akkermansia Muciniphilia in Combating the Metabolic Effects of Androgen Deprivation Therapy in Men With Metastatic Prostate CancerStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Product
Apple Cider VinegarDrug
VarlilumabClinical trial
Cardiovascular Risk in Epilepsy: Pilot Feasibility and Efficacy Study of Neurologist-Initiated Treatment of Hypertension and Hyperlipidemia in an Underserved Minority Population in Los AngelesStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
Cholesterol Reduction With Evolocumab and Coronary MicrovascuLar Function and Coronary Flow: The CHORAL Flow StudyStatus: Terminated, Estimated PCD: 2022-03-27
Clinical trial
Evaluation of the Efficacy and Safety of Multiple Subcutaneous Injections of SHR-1918 in Patients With Hyperlipidemia in Poor Control: a Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical TrialsStatus: Not yet recruiting, Estimated PCD: 2025-04-01